Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

出版年份 2017 全文链接

标题

作者

关键词

PRI-724, Liver cirrhosis, HCV, Wnt inhibitor

出版物

EBioMedicine

Volume 23, Issue -, Pages 79-87

出版商

Elsevier BV

发表日期

2017-08-20

DOI

10.1016/j.ebiom.2017.08.016

向作者/读者发起求助以获取更多资源

Protocol

在线求助

Reagent

在线求助

Reprint

联系作者

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started